カテゴリ： GlobalData, アメリカ, 企業調査

Global Blood Therapeutics Inc (GBT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Global Blood Therapeutics Inc (GBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8250
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company’s lead drug candidate GBT440 is an oral, small molecule drug for the treatment of sickle cell disease. Its GBT440 is a hemoglobin modifier which targets the mechanism of red blood cell sickling for the treatment of SCD. GBT’s pipeline also includes an oral kallikrein inhibitor to prevent hereditary angioedema attacks. The company also develops therapies which are in preclinical and preliminary clinical stage for the treatment of for acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms of blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Global Blood Therapeutics Inc (GBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Global Blood Therapeutics Raises USD48 Million in Series B Financing 11
Global Blood Therapeutics Raises US$50 Million In Series A Financing 13
Partnerships 14
HitGen Enters into Research Agreement with Global Blood Therapeutics 14
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15
Licensing Agreements 16
Global Blood Therapeutics Enters into Licensing Agreement with Roche 16
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18
Equity Offering 19
Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19
Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21
Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23
Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25
Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27
Global Blood Therapeutics Raises Funds through Private Placement of Shares 29
Acquisition 30
Novo Nordisk May Acquire Global Blood Therapeutics 30
Global Blood Therapeutics Inc – Key Competitors 31
Global Blood Therapeutics Inc – Key Employees 32
Global Blood Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
Aug 02, 2018: Global Blood Therapeutics reports second quarter 2018 financial results 34
May 07, 2018: Global Blood Therapeutics Announces First Quarter 2018 Financial Results 36
Feb 27, 2018: GBT Reports Fourth Quarter and Year-End 2017 Financial Results 37
Nov 02, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results 38
Aug 07, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results 40
May 01, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results 42
Mar 13, 2017: Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results 43
Corporate Communications 45
Dec 22, 2017: GBT Appoints Wendy L. Yarno to Board of Directors 45
Product News 46
10/24/2017: Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 46
10/11/2017: Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype 47
10/03/2017: Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October 49
02/14/2017: Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters 50
Product Approvals 51
Sep 05, 2017: Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease 51
Jun 28, 2017: Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) 52
Clinical Trials 53
Oct 23, 2017: Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program 53
Jul 10, 2017: Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population 54
Jun 23, 2017: Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease 55
May 18, 2017: Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress 56
Feb 16, 2017: Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions 57
Jan 18, 2017: Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Global Blood Therapeutics Raises USD48 Million in Series B Financing 11
Global Blood Therapeutics Raises US$50 Million In Series A Financing 13
HitGen Enters into Research Agreement with Global Blood Therapeutics 14
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15
Global Blood Therapeutics Enters into Licensing Agreement with Roche 16
Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18
Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19
Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21
Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23
Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25
Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27
Global Blood Therapeutics Raises Funds through Private Placement of Shares 29
Novo Nordisk May Acquire Global Blood Therapeutics 30
Global Blood Therapeutics Inc, Key Competitors 31
Global Blood Therapeutics Inc, Key Employees 32

List of Figures
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Global Blood Therapeutics Inc (GBT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • New Zealand Pharmaceuticals Ltd：企業の戦略的SWOT分析
    New Zealand Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Headwater Exploration Inc (HWX)：企業の財務・戦略的SWOT分析
    Summary Headwater Exploration Inc (Headwater), formerly Corridor Resources Inc, is an oil and gas company. It is engaged in exploring, producing and developing of petroleum and natural gas products. The company’s core operating areas include McCully Field in New Brunswick, Anticosti Island in Quebec …
  • Modine Manufacturing Company：企業の戦略・SWOT・財務情報
    Modine Manufacturing Company - Strategy, SWOT and Corporate Finance Report Summary Modine Manufacturing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SciGen Ltd (SIE)：製薬・医療：M&Aディール及び事業提携情報
    Summary SciGen Ltd (SciGen), a subsidiary of Bioton SA is a biotechnology company that manufactures, develops, and markets recombinant human health care biotechnology derived products. The company’s products include second generation recombinant human insulin, recombinant human growth hormone and si …
  • Anavex Life Sciences Corp (AVXL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The c …
  • OTE Group：企業の戦略・SWOT・財務情報
    OTE Group - Strategy, SWOT and Corporate Finance Report Summary OTE Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Acorda Therapeutics Inc (ACOR)：企業の財務・戦略的SWOT分析
    Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Advaxis Inc (ADXS)：企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Brown Brothers Harriman & Co：企業の戦略的SWOT分析
    Brown Brothers Harriman & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Dermira Inc (DERM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Fabric Genomics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Fabric Genomics Inc (Fabric), formerly Omicia Inc is a healthcare solutions provider that offers genome analysis services. The company provides solutions for researchers and clinicians to analyze genomes and disease-causing variants and genes. Its products include opal software and standalon …
  • Agenus Inc (AGEN)：企業の財務・戦略的SWOT分析
    Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vivus, Inc.：企業の戦略・SWOT・財務分析
    Vivus, Inc. - Strategy, SWOT and Corporate Finance Report Summary Vivus, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • IGas Energy PLC (IGAS)：企業の財務・戦略的SWOT分析
    IGas Energy PLC (IGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Danone SA：戦略・SWOT・企業財務分析
    Danone SA - Strategy, SWOT and Corporate Finance Report Summary Danone SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Cardiac Dimensions Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cardiac Dimensions Inc (Cardiac Dimensions) is a medical equipment company that develops intervention tools used for treating heart failure and other related cardiovascular conditions. The company develops carillon mitral contour system, a coronary sinus-based percutaneous mitral annuloplast …
  • Landsvirkjun hf：電力：M&Aディール及び事業提携情報
    Summary Landsvirkjun hf (Landsvirkjun) is a state-owned energy utility that conducts the generation and transmission of electricity in Iceland. It generates electricity through several renewable sources such as hydro, geothermal, and wind. Through subsidiaries, the company also offers telecommunicat …
  • Teleflex Incorporated：戦略・SWOT・企業財務分析
    Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report Summary Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • APR Energy Ltd：企業の戦略的SWOT分析
    APR Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Amarin Corp Plc (AMRN)：企業の財務・戦略的SWOT分析
    Amarin Corp Plc (AMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆